Extracellular vesicle-mediated miR135a-5p transfer in hypertensive rat contributes to vascular smooth muscle cell proliferation via targeting FNDC5. 2021

Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center of Translational Medicine for Cardiovascular Disease, Department of Physiology, Nanjing Medical University, Nanjing 211166, China.

Background Extracellular vesicles (EVs) from vascular adventitial fibroblasts (AFs) contribute to the proliferation of vascular smooth muscle cells (VSMCs) and vascular remodeling in spontaneously hypertensive rat (SHR). This study shows the crucial roles of EVs-mediated miR135a-5p transfer in VSMC proliferation and the underlying mechanisms in hypertension. Methods AFs and VSMCs were obtained from the aorta of Wistar-Kyoto rat (WKY) and SHR. EVs were isolated from the culture of AFs with ultracentrifugation method. Results MiR135a-5p level in SHR-EVs was significantly increased. MiR135a-5p inhibitor prevented the SHR-EVs-induced VSMC proliferation. Fibronectin type III domain containing 5 (FNDC5) was a target gene of miR135a-5p. FNDC5 level was lower in VSMCs of SHR. MiR135a-5p inhibitor not only increased FNDC5 expression, but reversed the SHR-EVs-induced FNDC5 downregulation in VSMCs of SHR. MiR135a-5p mimic inhibited FNDC5 expression, but failed to promote the SHR-EVs-induced FNDC5 downregulation in VSMCs of SHR. Exogenous FNDC5 prevented the SHR-EVs-induced VSMC proliferation of both WKY and SHR. Knockdown of miR135a-5p in fibroblasts completely prevented the upregulation of miR135a-5p in the EVs. The SHR-EVs from the miR135a-5p knockdown-treated fibroblasts lost their roles in inhibiting FNDC5 expression and promoting proliferation in VSMCs of both WKY and SHR. Conclusions Increased miR135a-5p in the SHR-EVs promoted VSMC proliferation of WKY and SHR via inhibiting FNDC5 expression. MiR135a-5p and FNDC5 are crucial targets for intervention of VSMC proliferation in hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D000067128 Extracellular Vesicles Membrane limited structures derived from cell membranes and cytoplasmic material, and released into EXTRACELLULAR SPACE. They circulate through the EXTRACELLULAR FLUID and through the peripheral blood in the MICROVASCULATURE where cells, much larger, cannot, thereby affecting a variety of intercellular communication processes. Apoptotic Bodies,Exovesicles,Apoptotic Body,Bodies, Apoptotic,Body, Apoptotic,Exovesicle,Extracellular Vesicle,Vesicle, Extracellular,Vesicles, Extracellular
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D032389 Myocytes, Smooth Muscle Non-striated, elongated, spindle-shaped cells found lining the digestive tract, uterus, and blood vessels. They are derived from specialized myoblasts (MYOBLASTS, SMOOTH MUSCLE). Smooth Muscle Cells,Cell, Smooth Muscle,Cells, Smooth Muscle,Myocyte, Smooth Muscle,Smooth Muscle Cell,Smooth Muscle Myocyte,Smooth Muscle Myocytes

Related Publications

Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
August 2021, Biomedicines,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
October 2016, Experimental and therapeutic medicine,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
January 2021, Oxidative medicine and cellular longevity,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
April 2021, Annals of translational medicine,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
July 2019, Microvascular research,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
January 2019, Frontiers in genetics,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
February 2023, Physiological genomics,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
February 2023, Aging cell,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
September 2015, Biochimica et biophysica acta,
Ying Tong, and Chao Ye, and Fen Zheng, and Jin-Hua Bo, and Lu-Lu Wu, and Ying Han, and Ye-Bo Zhou, and Xiao-Qing Xiong, and Qi Chen, and Yue-Hua Li, and Yu-Ming Kang, and Guo-Qing Zhu
September 2020, Circulation research,
Copied contents to your clipboard!